Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Literature DB >> 24136414

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Isabelle Huys¹, Jean-Paul Pirnay, Rob Lavigne, Serge Jennes, Daniel De Vos, Minne Casteels, Gilbert Verbeken.

Abstract

Mesh：

Substances：
Anti-Bacterial Agents

Year: 2013 PMID： 24136414 PMCID： PMC3818076 DOI： 10.1038/embor.2013.163

Source DB: PubMed Journal: EMBO Rep ISSN： 1469-221X Impact factor: 8.807

× No keyword cloud information.

5 in total

1. The phage therapy paradigm: prêt-à-porter or sur-mesure?

Authors: Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Maia Merabishvili; Nina Chanishvili; Mario Vaneechoutte; Martin Zizi; Geert Laire; Rob Lavigne; Isabelle Huys; Guy Van den Mooter; Angus Buckling; Laurent Debarbieux; Flavie Pouillot; Joana Azeredo; Elisabeth Kutter; Alain Dublanchet; Andrzej Górski; Revaz Adamia
Journal: Pharm Res Date: 2010-11-10 Impact factor: 4.200

Review 2. Bacteriophages as potential new therapeutics to replace or supplement antibiotics.

Authors: Mzia Kutateladze; Revaz Adamia
Journal: Trends Biotechnol Date: 2010-08-31 Impact factor: 19.536

Review 3. Tackling antibiotic resistance.

Authors: Karen Bush; Patrice Courvalin; Gautam Dantas; Julian Davies; Barry Eisenstein; Pentti Huovinen; George A Jacoby; Roy Kishony; Barry N Kreiswirth; Elizabeth Kutter; Stephen A Lerner; Stuart Levy; Kim Lewis; Olga Lomovskaya; Jeffrey H Miller; Shahriar Mobashery; Laura J V Piddock; Steven Projan; Christopher M Thomas; Alexander Tomasz; Paul M Tulkens; Timothy R Walsh; James D Watson; Jan Witkowski; Wolfgang Witte; Gerry Wright; Pamela Yeh; Helen I Zgurskaya
Journal: Nat Rev Microbiol Date: 2011-11-02 Impact factor: 60.633

4. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

Authors: Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein
Journal: Clin Infect Dis Date: 2009-10-15 Impact factor: 9.079

5. Bacteriophage adhering to mucus provide a non-host-derived immunity.

Authors: Jeremy J Barr; Rita Auro; Mike Furlan; Katrine L Whiteson; Marcella L Erb; Joe Pogliano; Aleksandr Stotland; Roland Wolkowicz; Andrew S Cutting; Kelly S Doran; Peter Salamon; Merry Youle; Forest Rohwer
Journal: Proc Natl Acad Sci U S A Date: 2013-05-20 Impact factor: 11.205

5 in total

13 in total

1. Experimental phage therapy of burn wound infection: difficult first steps.

Authors: Thomas Rose; Gilbert Verbeken; Daniel De Vos; Maya Merabishvili; Mario Vaneechoutte; Rob Lavigne; Serge Jennes; Martin Zizi; Jean-Paul Pirnay
Journal: Int J Burns Trauma Date: 2014-10-26

2. Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines.

Authors: Alan Fauconnier
Journal: EMBO Rep Date: 2017-01-12 Impact factor: 8.807

Review 3. Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

Authors: Katherine M Caflisch; Robin Patel
Journal: J Clin Microbiol Date: 2019-07-26 Impact factor: 5.948

4. The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.

Authors: Marine Henry; Louis-Marie Bobay; Anne Chevallereau; Emilie Saussereau; Pieter-Jan Ceyssens; Laurent Debarbieux
Journal: PLoS One Date: 2015-01-28 Impact factor: 3.240

10. Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo.

Authors: Kyoungeun Cha; Hynu K Oh; Jae Y Jang; Yunyeol Jo; Won K Kim; Geon U Ha; Kwan S Ko; Heejoon Myung
Journal: Front Microbiol Date: 2018-04-10 Impact factor: 5.640

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

1. The phage therapy paradigm: prêt-à-porter or sur-mesure?

Review 2. Bacteriophages as potential new therapeutics to replace or supplement antibiotics.

Review 3. Tackling antibiotic resistance.

4. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

5. Bacteriophage adhering to mucus provide a non-host-derived immunity.

1. Experimental phage therapy of burn wound infection: difficult first steps.

2. Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines.

Review 3. Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

4. The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.

Review 5. One cannot rule them all: Are bacterial toxins-antitoxins druggable?

Review 6. Structure, Biology, and Therapeutic Application of Toxin-Antitoxin Systems in Pathogenic Bacteria.

Review 7. Criteria for Selecting Suitable Infectious Diseases for Phage Therapy.

8. Transcriptomic Analysis of the Campylobacter jejuni Response to T4-Like Phage NCTC 12673 Infection.

Review 9. Phages preying on Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis: past, present and future.

10. Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo.